Q32 Bio Inc. (QTTB)Healthcare | Biotechnology | Waltham, United States | NasdaqCM
15.03 USD
-1.12
(-6.935%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 15.03 |
Hot Take ↕ | Aug. 22, 2026, 1:26 a.m. EDT
The investment case here is fundamentally broken. While the company boasts impressive headline numbers like a 72% return on equity and a 63% profit margin, these figures are artifacts of a tiny denominator following a catastrophic 95% stock price collapse last year. The business has suffered a structural implosion, evidenced by a nearly 99% loss of value over the past seven years and a single year of -95% performance. This is not a 'value trap' where the market is overly pessimistic; the price action confirms the market has correctly identified a deteriorating asset. The recent surge in news regarding public offerings and a 13G filing indicates the company is raising capital to survive, which often signals distress rather than opportunity. With no dividend to provide income and a balance sheet that appears fragile given the need for constant fundraising, there is no margin of safety. The options market agrees, with heavy put positioning suggesting fear of further declines. Avoid this security entirely. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.134152 |
| MSTL | 0.266888 |
| AutoETS | 0.294657 |
| AutoARIMA | 0.298848 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 1.91 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.157 |
| Excess Kurtosis | 0.69 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 5.001 |
| Revenue per Share | 3.622 |
| Market Cap | 447,435,072 |
| Trailing P/E | 4.79 |
| Forward P/E | -14.74 |
| Beta | -0.33 |
| Profit Margins | 62.87% |
| Website | https://www.q32bio.com |
As of Aug. 22, 2026, 1:26 a.m. EDT: Speculators are heavily positioned for downside protection, with open interest concentrated deep out-of-the-money on puts (strikes 10.0 and 12.5) across all expirations, while call activity remains sparse and focused on moderate strikes. The massive put volume relative to calls suggests a market consensus expecting further volatility or a drop below current levels, despite the recent price recovery.
| Attribute | Value |
|---|---|
| 52 Week Change | 8.444445 |
| Address1 | 830 Winter Street |
| All Time High | 572.4 |
| All Time Low | 1.345 |
| Ask | 19.36 |
| Ask Size | 2 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 375,080 |
| Average Daily Volume3 Month | 1,175,132 |
| Average Volume | 1,175,132 |
| Average Volume10Days | 375,080 |
| Beta | -0.329 |
| Bid | 11.45 |
| Bid Size | 2 |
| Book Value | 4.462 |
| City | Waltham |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 15.03 |
| Current Ratio | 20.301 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 16.25 |
| Day Low | 14.92 |
| Debt To Equity | 5.001 |
| Display Name | Q32 Bio |
| Earnings Timestamp End | 1,762,432,200 |
| Earnings Timestamp Start | 1,762,432,200 |
| Ebitda | 21,818,000 |
| Ebitda Margins | 0.40601003 |
| Enterprise To Ebitda | 15.88 |
| Enterprise To Revenue | 6.447 |
| Enterprise Value | 346,461,088 |
| Eps Current Year | -1.13 |
| Eps Forward | -1.02 |
| Eps Trailing Twelve Months | 3.14 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 14.8343 |
| Fifty Day Average Change | 0.19569969 |
| Fifty Day Average Change Percent | 0.013192378 |
| Fifty Two Week Change Percent | 844.44446 |
| Fifty Two Week High | 23.57 |
| Fifty Two Week High Change | -8.54 |
| Fifty Two Week High Change Percent | -0.36232498 |
| Fifty Two Week Low | 1.62 |
| Fifty Two Week Low Change | 13.41 |
| Fifty Two Week Low Change Percent | 8.277778 |
| Fifty Two Week Range | 1.62 - 23.57 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,522,243,800,000 |
| Float Shares | 14,474,510 |
| Forward Eps | -1.02 |
| Forward P E | -14.735294 |
| Free Cashflow | 19,392,250 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 22 |
| Fullday Change | -1.12 |
| Fullday Change Percent | -6.93498 |
| Fullday Price | 15.03 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.73301005 |
| Gross Profits | 39,390,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.028239999 |
| Held Percent Institutions | 0.76265997 |
| Implied Shares Outstanding | 29,769,466 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,711,411,200 |
| Last Split Factor | 1:18 |
| Long Business Summary | Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction. The company is developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody which completed Phase 2a clinical trials, designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin for the treatment of atopic dermatitis and alopecia areata. It also develops ADX-096, a C3d mAb CR1 fusion protein for use in ophthalmologic indications, as well as other C3d mAb fusions and nanobodies designed for tissue-targeted complement inhibition and a range of other indications. The company was founded in 2017 and is based in Waltham, Massachusetts. |
| Long Name | Q32 Bio Inc. |
| Market | us_market |
| Market Cap | 447,435,072 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_669405676 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | 33,786,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 480,776,875 |
| Number Of Analyst Opinions | 5 |
| Open | 16.075 |
| Operating Cashflow | -19,828,000 |
| Operating Margins | 0.39938998 |
| Payout Ratio | 0.0 |
| Phone | 781 999 0232 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 15.03 |
| Post Market Time | 1,787,960,584 |
| Previous Close | 16.15 |
| Price Eps Current Year | -13.300885 |
| Price Hint | 2 |
| Price To Book | 3.3684447 |
| Price To Sales Trailing12 Months | 8.326387 |
| Profit Margins | 0.62873 |
| Quick Ratio | 19.779 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | -1.12 |
| Regular Market Change Percent | -6.93498 |
| Regular Market Day High | 16.25 |
| Regular Market Day Low | 14.92 |
| Regular Market Day Range | 14.92 - 16.25 |
| Regular Market Open | 16.075 |
| Regular Market Previous Close | 16.15 |
| Regular Market Price | 15.03 |
| Regular Market Time | 1,787,947,200 |
| Regular Market Volume | 353,142 |
| Return On Assets | 0.14741999 |
| Return On Equity | 0.72138 |
| Revenue Per Share | 3.622 |
| Sand P52 Week Change | 0.1966995 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 29,769,466 |
| Shares Percent Shares Out | 0.105399996 |
| Shares Short | 3,137,680 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 2,263,602 |
| Short Name | Q32 Bio Inc. |
| Short Percent Of Float | 0.1497 |
| Short Ratio | 3.02 |
| Source Interval | 15 |
| State | MA |
| Symbol | QTTB |
| Target High Price | 59.0 |
| Target Low Price | 34.0 |
| Target Mean Price | 41.0 |
| Target Median Price | 36.0 |
| Total Cash | 106,270,000 |
| Total Cash Per Share | 3.57 |
| Total Debt | 5,296,000 |
| Total Revenue | 53,737,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | 3.14 |
| Trailing P E | 4.786624 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 7.693775 |
| Two Hundred Day Average Change | 7.3362246 |
| Two Hundred Day Average Change Percent | 0.9535273 |
| Type Disp | Equity |
| Volume | 353,142 |
| Website | https://www.q32bio.com |
| Zip | 2,451 |